Coenzyme Q10 (CoQ10) is a naturally occurring antioxidant that supports cellular energy production and protects against oxidative stress—two processes central to liver health. Non-alcoholic fatty liver disease (NAFLD) affects up to 30% of UK adults and is closely linked to obesity, type 2 diabetes, and metabolic syndrome. Emerging research has explored whether CoQ10 supplementation might benefit people with fatty liver by reducing liver enzyme levels and supporting mitochondrial function. Whilst preliminary studies show promise, CoQ10 is not currently recommended in NICE guidance as a standard treatment for NAFLD. This article examines the evidence, practical considerations, and how CoQ10 fits within the broader management of fatty liver disease.

What Is CoQ10 and How Does It Work in the Body?

Coenzyme Q10 (CoQ10), also known as ubiquinone, is a naturally occurring compound found in virtually every cell of the human body. It plays a crucial role in cellular energy production within the mitochondria—the powerhouses of our cells—where it participates in the electron transport chain to generate adenosine triphosphate (ATP), the primary energy currency of cells. Beyond energy metabolism, CoQ10 functions as a potent antioxidant, protecting cell membranes and lipoproteins from oxidative damage caused by free radicals.

The body produces CoQ10 endogenously, with highest concentrations found in organs with high metabolic demands such as the heart, liver, and kidneys. However, natural production declines with age, typically beginning after the age of 30. Additionally, certain medications—particularly statins used for cholesterol management—can reduce circulating CoQ10 levels, as these drugs inhibit the same biochemical pathway responsible for CoQ10 synthesis. However, UK guidance does not recommend routine CoQ10 supplementation for people taking statins, as there is insufficient evidence that it prevents statin-related side effects. Any decision to use CoQ10 alongside statins should be discussed with your GP or pharmacist.

CoQ10 exists in two forms: ubiquinone (the oxidised form) and ubiquinol (the reduced, active antioxidant form). The body can convert between these forms as needed. Dietary sources include oily fish (such as mackerel and sardines), organ meats (particularly liver and heart), whole grains, and certain vegetables, though the amounts obtained through diet alone are relatively modest compared to supplemental doses.

In the context of liver health, CoQ10's dual role as an energy facilitator and antioxidant has generated research interest. The liver, being central to metabolism and detoxification, has substantial energy requirements and is particularly vulnerable to oxidative stress—both factors implicated in the development and progression of fatty liver disease. Understanding these mechanisms provides the foundation for exploring CoQ10's potential therapeutic applications in hepatic conditions.

Understanding Fatty Liver Disease: Causes and Risk Factors

Non-alcoholic fatty liver disease (NAFLD) is characterised by excessive fat accumulation in the liver (hepatic steatosis) in individuals who consume little to no alcohol. It represents a spectrum of conditions, ranging from simple steatosis to non-alcoholic steatohepatitis (NASH), which involves inflammation and hepatocyte damage, potentially progressing to fibrosis, cirrhosis, and hepatocellular carcinoma. NAFLD has become the most common chronic liver condition in the UK, affecting an estimated 20–30% of the general population.

The pathophysiology of NAFLD is complex and multifactorial. Insulin resistance is considered a key driver, leading to increased hepatic lipogenesis (fat production) and reduced fat oxidation. This creates an environment of lipotoxicity, where excess lipids generate reactive oxygen species, triggering oxidative stress and inflammatory cascades. Mitochondrial dysfunction further compounds the problem, impairing the liver's ability to metabolise fats efficiently.

Major risk factors for NAFLD include:

• Obesity, particularly central adiposity

• Type 2 diabetes mellitus and metabolic syndrome

• Dyslipidaemia (elevated triglycerides, low HDL cholesterol)

• Hypertension

• Polycystic ovary syndrome (PCOS)

• Certain medications (corticosteroids, tamoxifen, methotrexate)

• Rapid weight loss or malnutrition

NAFLD is often asymptomatic in early stages, typically discovered incidentally through elevated liver enzymes (ALT, AST) on routine blood tests or abnormal findings on abdominal imaging. However, liver enzymes can be normal in people with NAFLD, so diagnosis and risk assessment should not rely on blood tests alone. According to NICE guidance (NG49), diagnosis involves excluding other causes of liver disease (viral hepatitis, alcohol-related liver disease, autoimmune conditions, haemochromatosis) through careful history-taking and appropriate blood tests.

Assessing fibrosis risk is essential, as advanced fibrosis determines prognosis and need for specialist care. NICE recommends the Enhanced Liver Fibrosis (ELF) test to detect advanced fibrosis in adults with NAFLD. An ELF score of 10.51 or above suggests advanced fibrosis and warrants referral to a hepatologist. For those at lower risk, repeat ELF testing approximately every three years helps monitor disease progression. Non-invasive tests such as transient elastography (FibroScan) may also be used to assess liver stiffness.

Seek urgent medical assessment if you develop:

• Jaundice (yellowing of skin or eyes)

• Ascites (abdominal swelling from fluid)

• Confusion or altered mental state (hepatic encephalopathy)

• Vomiting blood or passing black, tarry stools

• Signs of infection with liver disease

• Rapidly worsening liver blood tests

Your GP will coordinate initial investigations and refer you to a hepatology specialist if advanced fibrosis is suspected or if there are features of decompensated liver disease.

The Evidence: CoQ10 and Fatty Liver Disease

Research investigating CoQ10 supplementation for fatty liver disease has produced some encouraging preliminary findings, though the evidence base remains limited and evolving. Several randomised controlled trials and meta-analyses have examined CoQ10's effects on liver enzymes, metabolic parameters, and markers of oxidative stress in patients with NAFLD, typically using doses of 100–200 mg daily for periods of 8–24 weeks.

Systematic reviews and meta-analyses have suggested that CoQ10 may contribute to modest reductions in liver enzymes, particularly alanine aminotransferase (ALT) and aspartate aminotransferase (AST), which are markers of hepatocellular injury. Some studies have also reported reductions in gamma-glutamyl transferase (GGT) levels. However, these improvements are not universal across all trials, and the clinical significance of enzyme reductions alone—without proven histological benefit—remains uncertain.

Some research has reported favourable changes in lipid profiles and inflammatory markers, including reductions in total cholesterol, triglycerides, C-reactive protein (CRP), and tumour necrosis factor-alpha (TNF-α), though findings have been inconsistent across studies. The proposed mechanisms underlying any potential benefits relate to CoQ10's antioxidant properties and its role in mitochondrial function. By reducing oxidative stress, CoQ10 may help protect hepatocytes from lipotoxic damage. Furthermore, by supporting mitochondrial energy production, it may enhance the liver's capacity to metabolise accumulated fats. Some research suggests CoQ10 may also influence insulin sensitivity, addressing one of the fundamental drivers of NAFLD.

However, it is important to emphasise that there is no official consensus establishing CoQ10 as a standard treatment for fatty liver disease. Study populations have been relatively small, intervention durations varied, optimal dosing remains unclear, and crucially, evidence for histological improvement (changes in liver tissue structure, inflammation, or fibrosis on biopsy) is lacking. The MHRA has not approved CoQ10 specifically for treating NAFLD, and it is not included in NICE guidelines as a recommended therapy. Most available CoQ10 products are classified as food supplements rather than medicines, meaning they are not subject to the same rigorous regulatory standards as licensed medications.

Patients should view CoQ10 as a potential adjunctive measure that may support overall metabolic health, rather than a replacement for established lifestyle interventions and medical management. Any decision to use CoQ10 should be made in consultation with your GP or hepatologist, and it should complement—not substitute—evidence-based treatments.

How to Use CoQ10 Safely for Liver Health

For individuals considering CoQ10 supplementation in the context of fatty liver disease, several practical and safety considerations warrant attention. Typical supplemental doses used in clinical studies range from 100 to 200 mg daily, though some trials have employed doses up to 300–400 mg. CoQ10 is fat-soluble, meaning absorption is enhanced when taken with meals containing dietary fats. The ubiquinol form may offer superior bioavailability compared to ubiquinone, particularly in older adults or those with absorption difficulties.

CoQ10 is generally considered well-tolerated with a favourable safety profile. Reported adverse effects are typically mild and may include gastrointestinal symptoms such as nausea, diarrhoea, or abdominal discomfort. Some individuals report headache, dizziness, or insomnia, particularly with higher doses. Dividing the daily dose (e.g., taking 100 mg twice daily rather than 200 mg once) may improve tolerability.

Important drug interactions should be considered. CoQ10 may reduce the effectiveness of warfarin due to its structural similarity to vitamin K. If you take warfarin and are considering CoQ10, discuss this with your GP or anticoagulation clinic first, as you may require more frequent INR monitoring and possible dose adjustments. Evidence for interactions with direct oral anticoagulants (DOACs) is not established. Individuals taking blood pressure medications should be aware that CoQ10 may have additive blood-pressure-lowering effects. Those on chemotherapy agents, particularly anthracyclines, should consult their oncologist, as CoQ10's antioxidant properties could theoretically interfere with treatment, though evidence is limited.

If you are planning surgery, discuss your use of CoQ10 with your surgical or anaesthetic team. Many centres advise stopping non-essential supplements one to two weeks before surgery, though guidance varies.

Before starting CoQ10 supplementation, patients should consult their GP or hepatologist, particularly if they have:

• Confirmed liver disease or abnormal liver function tests

• Diabetes (as CoQ10 may affect blood glucose)

• Pregnancy or breastfeeding (insufficient safety data)

It is crucial to emphasise that CoQ10 should not replace evidence-based lifestyle modifications or prescribed medications. Quality and content can vary significantly among food supplements, so choose products from reputable UK suppliers and discuss your choice with a pharmacist or GP. If you experience any suspected side effects from CoQ10 or any other supplement, you can report them via the MHRA Yellow Card Scheme (available at yellowcard.mhra.gov.uk or via the Yellow Card app). Inform all healthcare providers about supplement use to ensure coordinated care and avoid potential interactions.

Other Evidence-Based Treatments for Fatty Liver Disease

The cornerstone of NAFLD management remains lifestyle modification, with robust evidence supporting weight loss and increased physical activity. According to NICE guidance (NG49), evidence suggests that weight reduction of 7–10% or more of body weight can lead to significant improvements in liver fat, inflammation, and potentially fibrosis. Greater weight loss is associated with more substantial liver benefits. Weight loss should be gradual (0.5–1 kg per week) to avoid rapid mobilisation of fat, which can paradoxically worsen liver inflammation.

Dietary interventions should focus on:

• Reducing refined carbohydrates and added sugars, particularly fructose-containing beverages

• Adopting a Mediterranean-style diet rich in vegetables, fruits, whole grains, legumes, nuts, and olive oil

• Limiting saturated fats whilst incorporating omega-3 fatty acids from oily fish

• Moderating portion sizes to achieve caloric deficit

• Avoiding alcohol completely or limiting to within UK Chief Medical Officers' guidelines (no more than 14 units per week, spread over three or more days)

Physical activity recommendations include at least 150 minutes of moderate-intensity aerobic exercise weekly, combined with resistance training. Exercise benefits liver health independently of weight loss through improvements in insulin sensitivity and reduction of visceral adiposity.

Regarding pharmacological treatments, no medications are currently licensed specifically for NAFLD in the UK. Pioglitazone (a thiazolidinedione insulin sensitiser) and vitamin E (at doses of 800 IU daily) are sometimes used off-label in specialist hepatology care for adults with biopsy-proven NASH, following careful discussion of risks and benefits. Pioglitazone carries risks including weight gain, fluid retention, heart failure, and bone fracture. Vitamin E has long-term safety concerns. NICE advises that these treatments should be considered only in secondary care, with regular review and discontinuation if there is no response. They are not suitable for routine primary care use.

For patients with concurrent type 2 diabetes, GLP-1 receptor agonists (such as liraglutide or semaglutide) and SGLT2 inhibitors are used to improve blood glucose control and support weight loss. Whilst emerging evidence suggests potential liver benefits, these medications are not licensed for treating NAFLD and any hepatic improvements are secondary to their metabolic effects.

Management of cardiovascular risk factors is essential, as cardiovascular disease represents the leading cause of mortality in NAFLD patients. Statins are safe to use in people with NAFLD and should be prescribed to manage dyslipidaemia and reduce cardiovascular risk as indicated by standard risk assessment. Statins are not used to treat NAFLD itself. Blood pressure control and antiplatelet therapy (where indicated) are also important components of care.

Follow-up and monitoring should follow NICE NG49 guidance. Use the ELF test to assess fibrosis risk; if the ELF score is 10.51 or above, refer to hepatology. For those at lower risk, repeat ELF testing approximately every three years. Patients with advanced fibrosis or cirrhosis require specialist hepatology input and should follow NICE guidance (NG50) for cirrhosis management, including six-monthly ultrasound surveillance for hepatocellular carcinoma and assessment for varices (oesophageal and gastric varices that can bleed). Regular monitoring through blood tests, non-invasive fibrosis assessment, and clinical review helps track disease progression and treatment response.

For further information and support, the British Liver Trust provides accessible patient resources on NAFLD, lifestyle advice, and how to access specialist care.

Frequently Asked Questions